AIM ImmunoTech Announces Release of the Next CEO Corner Segment
AIM ImmunoTech Announces Release of the Next CEO Corner Segment
OCALA, Fla., April 11, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company"), today announced the next CEO Corner segment has been published on the Company's website. For the CEO Corner segment, Thomas Equels, Chief Executive Officer of AIM ImmunoTech, discussed the Company's recent news release regarding top-line interim data indicating that combining Ampligen (rintatolimod) with Keytruda (pembrolizumab) in the treatment of recurrent ovarian cancer may have a powerful synergistic effect that could be far more effective than pembrolizumab alone as a therapy for the disease.
The CEO Corner segment is now available here.
About AIM ImmunoTech Inc.
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company's lead product is a first-in-class investigational drug called Ampligen (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.
Investor Contact: JTC Team, LLC Jenene Thomas (833) 475-8247 AIM@jtcir.com
OCALA, Fla., April 11, 2024 — AIM ImmunoTech Inc. (NYSE American: AIM) ("AIM" or the "Company"), today announced the next CEO Corner segment has been published on the Company's website. For the CEO Corner segment, Thomas Equels, Chief Executive Officer of AIM ImmunoTech, discussed the Company's recent news release regarding top-line interim data indicating that combining Ampligen (rintatolimod) with Keytruda (pembrolizumab) in the treatment of recurrent ovarian cancer may have a powerful synergistic effect that could be far more effective than pembrolizumab alone as a therapy for the disease.
佛羅里達州奧卡拉，2024 年 4 月 11 日 — AIM ImmunoTech公司 紐約證券交易所美國股票代碼：AIM）（“AIM” 或 “公司”）今天宣佈，下一個首席執行官專欄已在公司網站上發佈。對於 首席執行官專區 部分，AIM ImmunoTech首席執行官托馬斯·埃克爾斯討論了該公司的情況 最近的新聞發佈 關於主要的中期數據，該數據表明，將Ampligen（rintatolimod）與Keytruda（pembrolizumab）聯合治療複發性卵巢癌可能具有強大的協同作用，可能比單獨作爲該疾病療法的pembrolizumab有效得多。
The CEO Corner segment is now available here.
首席執行官專區現已推出 這裏。
About AIM ImmunoTech Inc.
關於 AIM ImmunoTech Inc
AIM ImmunoTech Inc. is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, immune disorders and viral diseases, including COVID-19. The Company's lead product is a first-in-class investigational drug called Ampligen (rintatolimod), a dsRNA and highly selective TLR3 agonist immuno-modulator with broad spectrum activity in clinical trials for globally important cancers, viral diseases and disorders of the immune system.
AIM ImmunoTech Inc. 是一家免疫製藥公司，專注於研究和開發治療多種類型的癌症、免疫疾病和病毒性疾病（包括 COVID-19）的療法。該公司的主導產品是一種名爲Ampligen（rintatolimod）的同類首創研究藥物，它是一種dsRNA和高選擇性TLR3激動劑免疫調節劑，在全球重要的癌症、病毒性疾病和免疫系統疾病的臨床試驗中具有廣譜活性。
For more information, please visit aimimmuno.com and connect with the Company on X, LinkedIn, and Facebook.
欲了解更多信息，請訪問 amimmuni.com 並通過以下方式與公司聯繫 X， 領英，以及 Facebook。
Investor Contact: JTC Team, LLC Jenene Thomas (833) 475-8247 AIM@jtcir.com
投資者聯繫人：JTC Team, LLC Jenene Thomas (833) 475-8247 AIM@jtcir.com
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧